XERIS PHARMACEUTICALS INC's ticker is and the CUSIP is 98422LAA5. A total of 4 filers reported holding XERIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $15,398,773 | +35.8% | 13,975,000 | +7.7% | 0.22% | -49.3% |
| Q1 2023 | $11,338,334 | +39.6% | 12,975,000 | +30.1% | 0.43% | -13.8% |
| Q4 2022 | $8,120,249 | -12.3% | 9,975,000 | 0.0% | 0.50% | -24.5% |
| Q3 2022 | $9,254,000 | +4.8% | 9,975,000 | 0.0% | 0.66% | +37.1% |
| Q2 2022 | $8,827,000 | -24.5% | 9,975,000 | 0.0% | 0.48% | -13.8% |
| Q1 2022 | $11,690,000 | -3.9% | 9,975,000 | 0.0% | 0.56% | -7.0% |
| Q4 2021 | $12,163,000 | +8.4% | 9,975,000 | 0.0% | 0.60% | +8.9% |
| Q3 2021 | $11,222,000 | -29.1% | 9,975,000 | 0.0% | 0.55% | -6.9% |
| Q2 2021 | $15,819,000 | +1.7% | 9,975,000 | +8.4% | 0.59% | -1.0% |
| Q1 2021 | $15,547,000 | +18.7% | 9,200,000 | +23.5% | 0.60% | -28.5% |
| Q4 2020 | $13,103,000 | -9.3% | 7,450,000 | 0.0% | 0.84% | -28.9% |
| Q3 2020 | $14,444,000 | – | 7,450,000 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sessa Capital IM, L.P. | 7,450,000 | $13,103,000 | 0.84% |
| 683 Capital Management, LLC | 8,100,000 | $14,094,000 | 0.67% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 18,000,000 | $31,658,000 | 0.63% |
| Saltoro Capital, LP | 250,000 | $439,000 | 0.22% |
| UBS OCONNOR LLC | 2,000,000 | $3,461,000,000 | 0.07% |
| LAZARD ASSET MANAGEMENT LLC | 7,875,000 | $13,836,000 | 0.02% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4,000,000 | $6,948,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |